Pok Yu Chow Net Worth

The estimated Net Worth of Pok Yu Augustine Chow is at least $67.7 Thousand dollars as of 26 May 2011. Pok Chow owns over 34,542 units of Imunon Inc stock worth over $67,702 and over the last 16 years he sold CLSN stock worth over $0. In addition, he makes $0 as Independent Director at Imunon Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Pok Chow CLSN stock SEC Form 4 insiders trading

Pok has made over 1 trades of the Imunon Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 34,542 units of CLSN stock worth $95,681 on 26 May 2011.

The largest trade he's ever made was buying 34,542 units of Imunon Inc stock on 26 May 2011 worth over $95,681. On average, Pok trades about 1,439 units every 0 days since 2009. As of 26 May 2011 he still owns at least 34,542 units of Imunon Inc stock.

You can see the complete history of Pok Chow stock trades at the bottom of the page.

Pok Yu Chow biography

Dr. Pok Yu Chow, Ph.D., is Independent Director of Celsion Corporation., since March 14, 2007. Dr. Chow has served as the Chief Executive Officer of Harmony Asset Limited since 1996, an investment company listed on the Hong Kong Stock Exchange and specializing in China and Hong Kong. Dr. Chow has served as Executive Director of Kaisun Energy Group Ltd. since 2008 and currently serves as a director of Medifocus Inc. From 1990 to 1998, Dr. Chow was the Chief Executive Officer of Allied Group of Companies based in Hong Kong. Prior to this, Dr. Chow held a senior position with Brunswick Corporation and Outboard Marine Corporation and was responsible for all business activities in South East Asia and China. Dr. Chow’s qualifications include a number of Bachelors, Masters and Doctoral degrees. Among them include a MSc from London Business School, a Ph.D. from the University of South Australia, and an Engineering Doctorate and Ph.D. on Biology from City University of Hong Kong.

How old is Pok Chow?

Pok Chow is 63, he's been the Independent Director of Imunon Inc since 2007. There are 6 older and 6 younger executives at Imunon Inc. The oldest executive at Imunon Inc is Michael H. Tardugno, 70, who is the Exec. Chairman, Pres & CEO.

What's Pok Chow's mailing address?

Pok's mailing address filed with the SEC is C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648.

Insiders trading at Imunon Inc

Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link, and Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.

What does Imunon Inc do?

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.

Complete history of Pok Chow stock trades at Imunon Inc

Imunon Inc executives and stock owners

Imunon Inc executives and other stock owners filed with the SEC include:

• Michael Tardugno,
  Executive Chairman of the Board, President, Chief Executive Officer
• Michael H. Tardugno,
  Exec. Chairman, Pres & CEO
• Nicholas Borys,
  Senior Vice President and Chief Medical Officer
• Jeffrey Church,
  Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
• Dr. Nicholas Borys,
  Exec. VP & Chief Medical Officer
• Jeffrey W. Church CPA, CPA,
  CFO, Exec. VP & Corp. Sec.
• Dr. Khursheed Anwer M.B.A., Ph.D.,
  Exec. VP & Chief Scientific Officer
• Khursheed Anwer,
  Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
• Dr. Khursheed Anwer,
  Exec. VP & Chief Scientific Officer
• Andreas Voss,
  Independent Director
• Alberto Martinez,
  Independent Director
• Robert Hooper,
  Independent Director
• Frederick Fritz,
  Independent Director
• Pok Yu Chow,
  Independent Director
• Donald Braun,
  Independent Director
• Marianne M. Lambertson,
  VP of Communications & Investor Relations
• Timothy J. Tumminello,
  Chief Accounting Officer & Controller
• Sean F. Moran,
  Chief Financial Officer
• Gary W Pace,
  Director
• Stacy Lindborg,
  Director
• Christine A Pellizzari,
  Director
• Timothy J Tumminello,
  Controller
• Inc. Fka Egen, Inc. Egwu,,
  10% owner
• Max Link,
  Director
• Gregory L Weaver,
  Director
• Goff Corinne Le,
  President and CEO
• Constantine John Kardaras,
  Chief Accounting Officer